Loncar Cancer Immunotherapy Etf Performance
| CNCR Etf | USD 10.10 0.40 3.81% |
The etf secures a Beta (Market Risk) of -0.24, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Loncar Cancer are expected to decrease at a much lower rate. During the bear market, Loncar Cancer is likely to outperform the market.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Loncar Cancer Immunotherapy has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Etf's fundamental indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the ETF retail investors. ...more
| In Threey Sharp Ratio | -0.51 |
Loncar |
Loncar Cancer Relative Risk vs. Return Landscape
If you would invest 1,261 in Loncar Cancer Immunotherapy on December 26, 2024 and sell it today you would lose (251.00) from holding Loncar Cancer Immunotherapy or give up 19.9% of portfolio value over 90 days. Loncar Cancer Immunotherapy is currently does not generate positive expected returns and assumes 2.2332% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of etfs are less volatile than Loncar, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Loncar Cancer Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Loncar Cancer's investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as Loncar Cancer Immunotherapy, and traders can use it to determine the average amount a Loncar Cancer's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1516
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CNCR |
Estimated Market Risk
| 2.23 actual daily | 19 81% of assets are more volatile |
Expected Return
| -0.34 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Loncar Cancer is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Loncar Cancer by adding Loncar Cancer to a well-diversified portfolio.
Loncar Cancer Fundamentals Growth
Loncar Etf prices reflect investors' perceptions of the future prospects and financial health of Loncar Cancer, and Loncar Cancer fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Loncar Etf performance.
| Price To Earning | 24.63 X | |||
| Price To Book | 1.99 X | |||
| Price To Sales | 1.24 X | |||
| Total Asset | 20.52 M | |||
About Loncar Cancer Performance
Assessing Loncar Cancer's fundamental ratios provides investors with valuable insights into Loncar Cancer's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Loncar Cancer is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. Loncar Cancer is traded on NASDAQ Exchange in the United States.| Loncar Cancer Immuno generated a negative expected return over the last 90 days | |
| Loncar Cancer Immuno created five year return of -9.0% | |
| This fund holds 99.87% of its assets under management (AUM) in equities |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Loncar Cancer Immunotherapy. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.